Blog
LL-37: why the larger ulcer trial’s overall result matters
The main result and a promising subgroup are different levels of evidence. Presenting only the subgroup would mislead readers about what the trial demonstrated.
Evidence discussed: Randomized phase IIb human trial.
What the researchers studied
A placebo-controlled trial enrolled 148 people with difficult-to-heal venous leg ulcers. It evaluated topical LL-37 alongside compression therapy. Analysis of the full population found no statistically significant healing improvement compared with placebo. [1]
How to interpret the result
A post-hoc analysis suggested possible benefit in larger wounds. That exploratory finding cannot replace the overall result and needs confirmation. A topical preparation also does not provide evidence for injectable research stock.
What readers can take from it
The main result and a promising subgroup are different levels of evidence. Presenting only the subgroup would mislead readers about what the trial demonstrated.
This original editorial summary provides no diagnosis, dosing or treatment advice. The study did not test or certify a PeptiKing product.
Source
[1] Mahlapuu et al., HEAL LL-37 ulcer trial (2021). PMID: 34687253. Based on the PubMed-indexed abstract and record; full-text methods were not independently reviewed.